A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer
Yochum Z, Cades J, Mazzacurati L, Neumann N, Khetarpal S, Chatterjee S, Wang H, Attar M, Huang E, Chatley S, Nugent K, Somasundaram A, Engh J, Ewald A, Cho Y, Rudin C, Tran P, Burns T. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Molecular Cancer Research 2017, 15: 1764-1776. PMID: 28851812, PMCID: PMC5712248, DOI: 10.1158/1541-7786.mcr-17-0298.Peer-Reviewed Original ResearchConceptsOncogene-driven NSCLCTwist1 functionPatient-derived xenograft mouse modelsMarked anti-tumor activityEpithelial-mesenchymal transition transcription factorsNon-small cell lung cancer tumorigenesisSolid tumor malignanciesSingle-cell disseminationLung cancer tumorigenesisNovel therapeutic strategiesXenograft mouse modelCell lung cancer tumorigenesisEffects of harmineAnti-tumor activityConnectivity mapping analysisE2A proteinsNSCLC cellsNSCLC tumorigenesisMutant NSCLCAnalogs/derivativesMouse modelTherapeutic strategiesHarmine treatmentDimer partnerTherapeutic target